ARA-290 (Cibinetide): The Innate Repair Receptor
An 11-amino-acid peptide derived from the B helix of erythropoietin โ but without raising hematocrit. It activates the innate repair receptor to modulate inflammation and neuropathic pain.
What ARA-290 is
ARA-290 (Cibinetide) is an 11-amino-acid peptide that reproduces the B helix of erythropoietin (EPO). Unlike EPO, it does not stimulate red blood cell production โ avoiding the thrombotic risk associated with raising hematocrit.
The innate repair receptor
ARA-290 acts on the innate repair receptor (IRR), a heterocomplex of the EPO receptor with the ฮฒ-common subunit (CD131). Its activation is anti-inflammatory and cytoprotective: it modulates macrophages and microglia and favors the resolution of tissue damage, without the erythropoietic pathway.
Published studies
The work of Brines and Cerami laid the groundwork for tissue-protective EPO. Early clinical trials (Dahan et al.) evaluated ARA-290 in sarcoidosis-associated small fiber neuropathy, with reported improvements in nerve fiber density and in pain questionnaires. It has also been studied in diabetic neuropathy. The evidence is early-phase.
Research dose ranges
Published protocols use daily SC doses in the low-milligram range over defined cycles. Descriptive context from the literature, not a clinical recommendation.
Related products
โ For research use only. Not medical advice.